{"title":"食管静脉曲张是肝性脑病患者接受球囊闭塞逆行经静脉阻塞术后致命后果的独立预测因素。","authors":"Shuichiro Iwasaki, Haruki Uojima, Shinya Sakita, Sakue Masuda, Kousuke Kubota, Tomoaki Fujikawa, Tomomi Okubo, Toru Setsu, Norio Itokawa, Yoshihiro Furuichi, Yoshitaka Arase, Toshiki Tukiyama, Kaoru Fujii, Hisashi Hidaka, Masanori Atsukawa, Tatehiro Kagawa, Makoto Kako, Shuji Terai, Chika Kusano","doi":"10.1159/000541660","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study was to evaluate esophageal varices (EVs) as predictors of poor prognosis with low tolerability after balloon-occluded retrograde transvenous obliteration (BRTO) in patients with overt hepatic encephalopathy (HE).</p><p><strong>Methods: </strong>This study retrospectively enrolled 107 patients who underwent BRTO for uncontrollable overt HE. The enrolled patients were divided into two groups based on the presence of EVs using propensity matching. The present study assessed the technical success rate and safety of BRTO in both the groups. Further, the event-free survival, HE-free survival, and the overall survival (OS) were compared between the two groups. Event-free survival was defined as the time period during which the patients did not developed complications related to portal hypertension, including EVs, hepatic ascites, and portal vein thrombosis.</p><p><strong>Results: </strong>After propensity matching, the EV and non-EV groups had 37 and 36 patients, respectively. Only 1 patient experienced an unsuccessful procedure in the EV group. Procedure-related adverse events in the EV group and non-EV group occurred in 11 and 7 patients, respectively (p = 0.417). The event-free survival after BRTO in the EV and non-EV group were 1,283 (95% CI: 798-1,767) days and 2,257 (1,722-2,792) days, respectively. Event-free survival was significantly worse in the EV group than in the non-EV group (p = 0.014). Furthermore, the EV group experienced worse OS than the non-EV group (p = 0.001 and p < 0.001, respectively).</p><p><strong>Conclusions: </strong>The presence of EVs could potentially be associated with a higher risk of adverse outcomes or mortality after BRTO treatment in individuals with HE.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Esophageal Varices as an Independent Predictor of Fatal Outcomes after Balloon-Occluded Retrograde Transvenous Obliteration in Patients with Hepatic Encephalopathy.\",\"authors\":\"Shuichiro Iwasaki, Haruki Uojima, Shinya Sakita, Sakue Masuda, Kousuke Kubota, Tomoaki Fujikawa, Tomomi Okubo, Toru Setsu, Norio Itokawa, Yoshihiro Furuichi, Yoshitaka Arase, Toshiki Tukiyama, Kaoru Fujii, Hisashi Hidaka, Masanori Atsukawa, Tatehiro Kagawa, Makoto Kako, Shuji Terai, Chika Kusano\",\"doi\":\"10.1159/000541660\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The objective of this study was to evaluate esophageal varices (EVs) as predictors of poor prognosis with low tolerability after balloon-occluded retrograde transvenous obliteration (BRTO) in patients with overt hepatic encephalopathy (HE).</p><p><strong>Methods: </strong>This study retrospectively enrolled 107 patients who underwent BRTO for uncontrollable overt HE. The enrolled patients were divided into two groups based on the presence of EVs using propensity matching. The present study assessed the technical success rate and safety of BRTO in both the groups. Further, the event-free survival, HE-free survival, and the overall survival (OS) were compared between the two groups. Event-free survival was defined as the time period during which the patients did not developed complications related to portal hypertension, including EVs, hepatic ascites, and portal vein thrombosis.</p><p><strong>Results: </strong>After propensity matching, the EV and non-EV groups had 37 and 36 patients, respectively. Only 1 patient experienced an unsuccessful procedure in the EV group. Procedure-related adverse events in the EV group and non-EV group occurred in 11 and 7 patients, respectively (p = 0.417). The event-free survival after BRTO in the EV and non-EV group were 1,283 (95% CI: 798-1,767) days and 2,257 (1,722-2,792) days, respectively. Event-free survival was significantly worse in the EV group than in the non-EV group (p = 0.014). Furthermore, the EV group experienced worse OS than the non-EV group (p = 0.001 and p < 0.001, respectively).</p><p><strong>Conclusions: </strong>The presence of EVs could potentially be associated with a higher risk of adverse outcomes or mortality after BRTO treatment in individuals with HE.</p>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000541660\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541660","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
摘要
背景:目的:评估食管静脉曲张(EVs)作为明显肝性脑病(HE)患者接受球囊闭塞逆行经静脉阻塞术(BRTO)后预后差且耐受性低的预测因素:本研究回顾性纳入了 107 例因无法控制的显性肝性脑病而接受 BRTO 的患者。根据EVs的存在情况,采用倾向匹配法将入组患者分为两组。本研究评估了两组患者 BRTO 的技术成功率和安全性。此外,还比较了两组患者的无事件生存期、无 HE 生存期和总生存期(OS)。无事件生存期是指患者在此期间未出现与门静脉高压相关的并发症,包括EV、肝腹水和门静脉血栓:倾向匹配后,EV 组和非 EV 组分别有 37 名和 36 名患者。EV组中只有一名患者手术不成功。EV组和非EV组分别有11名和7名患者发生了与手术相关的不良事件。(EV组和非EV组的BRTO术后无事件生存期分别为1,283天(95% CI:798 - 1,767)和2,257天(1,722 - 2,792)(P=0.417)。EV 组的无事件生存期明显低于非 EV 组(P=0.014)。此外,EV组的OS也比非EV组差(分别为P=0.001和P<0.001):结论:EV 的存在可能与 HE 患者接受 BRTO 治疗后出现不良预后或死亡的风险较高有关。
Esophageal Varices as an Independent Predictor of Fatal Outcomes after Balloon-Occluded Retrograde Transvenous Obliteration in Patients with Hepatic Encephalopathy.
Introduction: The objective of this study was to evaluate esophageal varices (EVs) as predictors of poor prognosis with low tolerability after balloon-occluded retrograde transvenous obliteration (BRTO) in patients with overt hepatic encephalopathy (HE).
Methods: This study retrospectively enrolled 107 patients who underwent BRTO for uncontrollable overt HE. The enrolled patients were divided into two groups based on the presence of EVs using propensity matching. The present study assessed the technical success rate and safety of BRTO in both the groups. Further, the event-free survival, HE-free survival, and the overall survival (OS) were compared between the two groups. Event-free survival was defined as the time period during which the patients did not developed complications related to portal hypertension, including EVs, hepatic ascites, and portal vein thrombosis.
Results: After propensity matching, the EV and non-EV groups had 37 and 36 patients, respectively. Only 1 patient experienced an unsuccessful procedure in the EV group. Procedure-related adverse events in the EV group and non-EV group occurred in 11 and 7 patients, respectively (p = 0.417). The event-free survival after BRTO in the EV and non-EV group were 1,283 (95% CI: 798-1,767) days and 2,257 (1,722-2,792) days, respectively. Event-free survival was significantly worse in the EV group than in the non-EV group (p = 0.014). Furthermore, the EV group experienced worse OS than the non-EV group (p = 0.001 and p < 0.001, respectively).
Conclusions: The presence of EVs could potentially be associated with a higher risk of adverse outcomes or mortality after BRTO treatment in individuals with HE.